The S-1 enables selling stockholders to dump up to 9.7M shares into a thin market ($9M market cap). Combined with 57.95M outstanding warrants deeply out of the money ($0.62 vs $0.27 stock), the overhang is severe. The May 19, 2026 Nasdaq compliance deadline is critical — failure to regain $1 bid price could trigger delisting. Monitor for any reverse stock split announcement or further dilutive financing.
Executive Summary
GT Biopharma filed an S-1 registration statement to register up to 9,723,057 shares of common stock for resale by selling stockholders, consisting of conversion shares, warrant shares, dividend shares, and advisory shares. The company will not receive any proceeds from the sale of these shares. The filing highlights a going concern qualification, Nasdaq non-compliance with the $1 minimum bid price requirement (compliance deadline May 19, 2026), and massive potential dilution from outstanding warrants (57.9M shares at $0.62 weighted average exercise price vs. $0.27 stock price).
Key Facts
- Registers 9,723,057 shares for resale by selling stockholders; company receives no proceeds.
- Going concern qualification from independent auditor (Weinberg & Company) in the 10-K for year ended Dec 31, 2025.
- Nasdaq non-compliance: stock closed below $1 for 30 consecutive days as of Nov 20, 2025; compliance period ends May 19, 2026.
- As of April 15, 2026, 35.6M shares outstanding, with 57.95M additional shares issuable upon exercise of warrants at a weighted average exercise price of $0.62.
- Stock closed at $0.27 on April 29, 2026, well below the $1 minimum bid price requirement.
- Gross proceeds of $9.4 million from Greenshoe Rights exercises used for working capital.
- Series L Preferred Stock carries a 10% annual dividend (12% after May 11, 2026), payable quarterly in cash or stock.
Financial Impact
Massive potential dilution: 57.95M warrant shares at $0.62 exercise price vs. $0.27 stock price, representing ~163% dilution of current 35.6M shares outstanding. Going concern risk with no revenue disclosed.
Risk Factors
- Nasdaq delisting risk if minimum bid price compliance not regained by May 19, 2026.
- Extreme dilution from 57.95M outstanding warrants exercisable at $0.62 vs $0.27 stock price.
- Going concern qualification — cash may not sustain operations through next 12 months.
- Selling stockholders can immediately resell 9.7M shares, creating massive supply overhang.
- No revenue or product revenue disclosed; pre-revenue clinical-stage biotech.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001493152-26-020697 |
| Exhibit: ex107.htm | 0001493152-26-020697 |
| Exhibit: ex5-1.htm | 0001493152-26-020697 |
| Exhibit: ex23-1.htm | 0001493152-26-020697 |
| Document: 0001493152-26-020697-index-headers.html | 0001493152-26-020697 |
| Document: 0001493152-26-020697-index.html | 0001493152-26-020697 |
| Document: 0001493152-26-020697.txt | 0001493152-26-020697 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $6.10 (+32.22%) |
Sep 3, 2026 29d ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $6.10 (+2316.80%) |
Aug 14, 2026 7w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $6.10 (−1960.81%) |
May 22, 2026 19w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $6.10 (−1286.36%) |
Apr 30, 2026 22w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $6.10 (−1678.43%) |
Apr 7, 2026 25w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $6.10 (+1377.00%) |
Mar 2, 2026 30w ago | Press Release | $0.4670 $0.4170 | ▼ −10.71% | ▼ −9.50% | $6.10 (+1206.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access